MARKET WIRETradingView • 16h ago
Vyome Holdings, Inc. Estimates – NASDAQ:HINDTradingView report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.
Why HIND Stock surged +2.86% Today — RQD Quant Desk Flash
$1.80 +2.86% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.81
Vyome Holdings Inc. (HIND) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $12.6M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on HIND Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is HIND stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Vyome Holdings Inc. (NASDAQ: HIND) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.80 (+2.86% 1D, market cap $12.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, HIND ranks #848 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does HIND compare to JAGX and BOLT in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HIND carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 68.4%, and ROIC of -35.0%. By comparison, JAGX (Jaguar Health Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M) and BOLT (Bolt Biotherapeutics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M). Among the 5-stock peer group, HIND leads on earnings multiple (N/A) while HIND leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for HIND?
▼
Per HIND's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001427570), Vyome Holdings Inc. generated $319.7K in revenue (-96.0% YoY), -$10.3M in net income, and -$3.7M in free cash flow against $6.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.81 (+0.32%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HIND)Realized 20D OHLCV Swing Band: ±10.7%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY HIND SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (28% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 21.9% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.97-6.6% Next Q
37
Q2 (-2Q)Grade E$1.84-7.6% Next Q
34
Q3 (-1Q)Grade E$1.70+5.9% Next Q
32
CurrentGrade E$1.80-9.8% Hist 90D α
29
Trajectory: E (37) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a HIND Turnaround Squeeze
While HIND currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.98) and Max Pain ($1.89) forces dealer call-delta covering toward $6.89.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $HIND• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HIND Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why HIND Stock surged +2.86% Today — RQD Quant Desk Flash
Vyome Holdings Inc. (HIND) surged +2.86% to $1.80, trading at 4% of its 52-week range ($1.62 – $6.56). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 4% of its 52-week range ($1.62 – $6.56) with RSI-14 at 42.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.7% around $1.80 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 21.9% gross margin and $0 annual free cash flow.
Live HIND Headlines & Catalysts
MARKET WIREYahoo Finance • 19h ago
Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical SchoolYahoo Finance report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 22h ago
Vyome at Chardan healthcare conference: lean biotech bets on rare woundsInvesting.com report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation MarketYahoo Finance report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
AZR Stock Price and Chart — BOATS:AZRTradingView report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.dars.gov.et/ • 1d ago
HIND Q2 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift Shares - Interim Reporthttps://www.dars.gov.et/ report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 1d ago
Vyome Holdings, Inc. (HIND) Stock Price Prediction for 2026, 2030-2040Traders Union report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HIND)
- ✓Walkthrough of HIND's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
HIND // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.88%▼ DESCENDING CHANNEL
2026-11-03O $1.75H $1.80L $1.75C $1.80VOL 42.2K
RES: $2.13SUP: $1.60SMA50: $1.98SMA200: $2.23
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
HIND Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on HIND today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for HIND. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HIND today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HIND)
Health Care Rank #848 of 1016
⚔️ JAGX vs HIND Full Matrix →
1. Head-to-Head Health Care Peer Comparison (HIND vs. JAGX, BOLT, BIVI, KTTA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Vyome Holdings Inc. (HIND) ranks #848 by composite RQD confidence (29/100, grade E) and #871 by equity capitalization ($12.6M). Within this direct 5-issuer industry benchmark cohort, HIND leads on earnings valuation at N/A trailing P/E, while HIND leads on capital efficiency and profitability with -35.0% ROIC and 68.4% gross margin. KTTA currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with HIND at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HIND
ACTIVE
Vyome Holdings Inc. | E | 29/100 | — | 68.4% | -35.0% | +2.86% | $12.6M | Benchmark Subject |
| JAGX Jaguar Health Inc. | E | 28/100 | — | 67.2% | -35.0% | -20.59% | $12.6M | /jagx-vs-hind → |
| BOLT Bolt Biotherapeutics Inc. | D- | 37/100 | — | — | -35.0% | +3.62% | $12.7M | /bolt-vs-hind → |
| BIVI BioVie Inc. (Class A) | E | 32/100 | — | — | -35.0% | +3.62% | $12.4M | /bivi-vs-hind → |
| KTTA Pasithea Therapeutics Corp. | D- | 40/100 | — | — | -35.0% | +0.16% | $12.4M | /ktta-vs-hind → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001427570In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vyome Holdings Inc. (HIND) reported GAAP revenue of $319.7K (-96.0% vs. FY2024 revenue of $8.0M , and -96.3% cumulative change since FY2023) , GAAP net income of -$10.3M, operating cash flow of -$3.7M, and free cash flow of -$3.7M (-510.4% YoY). On the balance sheet, HIND closed FY2025 with $6.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $319.7K | -$10.3M | -$3.7M | -$3.7M | $6.5M | — |
| FY2024 (FY) | 2024-12-31 | $8.0M | -$1.4M | -$614.1K | -$614.1K | $1.4M | — |
| FY2023 (FY) | 2023-12-31 | $8.7M | -$11.4M | -$17.0M | -$17.0M | — | — |
3. HIND Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs HIND stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Vyome Holdings Inc. (NASDAQ: HIND) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.80 (+2.86% 1D, market cap $12.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, HIND ranks #848 in composite RQD confidence.
How does HIND compare to JAGX and BOLT in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HIND carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 68.4%, and ROIC of -35.0%. By comparison, JAGX (Jaguar Health Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M) and BOLT (Bolt Biotherapeutics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M). Among the 5-stock peer group, HIND leads on earnings multiple (N/A) while HIND leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for HIND?
Per HIND's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001427570), Vyome Holdings Inc. generated $319.7K in revenue (-96.0% YoY), -$10.3M in net income, and -$3.7M in free cash flow against $6.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is HIND trading relative to its 50-day, 200-day, and 52-week technical levels?
HIND last traded at $1.80 (+2.86% on volume of 42,214 shares), positioning the stock -9.09% below its 50-day simple moving average ($1.98) and -19.28% below its 200-day simple moving average ($2.23). Across its 52-week range of $1.62 to $6.56, HIND sits at the 3.6% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±10.7% ($1.61 to $1.99).
HIND Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is HIND stock moving today?
Why HIND Stock surged +2.86% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 29/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
HIND — Vyome Holdings Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:51:17Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, HIND carries an RQD Score of 29 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 8 / 20 (ROIC -35%; FCF yield 0%), indicating the business is not currently converting capital into cash returns. Whale 13F Flow scores 3 / 20 for institutional accumulation and options positioning, and Insider Conviction scores 3 / 20 for SEC Form 4 and Congressional PTR cluster flow, both signaling weak smart-money support. Macro Regime Fit scores 7 / 20 with a Beta of 1.0 and sector sensitivity noted. Forensic Balance Sheet scores 8 / 20, reflecting an Altman Z of 2.5, a Piotroski F of 3/9, and Debt/Equity of 0.5.
For a prospective investor evaluating the stock today, the pillar profile points to a company where the cash engine, ownership signals, and forensic indicators all sit in weak territory simultaneously. Any upside case would need to rest on a catalyst that changes the cash-generation picture, since the current scores do not show that inflection. Valuation is difficult to anchor because trailing and forward earnings multiples are not available in source data, so the tradeoff cannot be framed against earnings. The rating is an analytical summary of the supplied data and is not personalized financial advice.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.3M | $-10.5M | $-10.3M | N/A | $-3.7M | $5.0M | N/A |
| FY 2024 | $8.0M | $-1.0M | $-1.4M | N/A | $-0.6M | $0.1M | N/A |
| FY 2023 | $8.7M | $-15.4M | $-11.4M | N/A | $-17.0M | N/A | N/A |
Per the Market Data, operating margin and net margin are both -60% and gross margin is 68.4%, with ROIC at -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with Debt/Equity at 0.5. Revenue fell from $8.0M in FY 2024 to $0.3M in FY 2025 per the SEC financials, while net loss widened to $-10.3M, making the FY 2025 margin profile the most pressing item in the period data. Balance sheet posture is reported as cash of $5.0M against FY 2025 free cash flow of $-3.7M.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts feed, the most material items are:
- Patent progress (YELLOW): A Yahoo Finance report indicates a USPTO Notice of Allowance for a U.S. patent covering VT-1908, framed as targeting a $20+ Billion ocular inflammation market.
- Leadership recognition (YELLOW): A co-founder was promoted to Professor at Harvard Medical School, per Yahoo Finance.
- Conference presence (YELLOW): Investing.com reported on a Chardan healthcare conference appearance.
- Risk Watch (RED): An item headlined as a Q2 2026 earnings report describes a narrower-than-expected loss that failed to lift shares; the summary field of this item is malformed and attributes content to a non-issuer domain, so its reliability should be treated cautiously.
Butterfly Supply-Chain Graph: Supply chain is NONE, with no butterfly links and no proprietary signals.
Open Questions
- What are the trailing and forward earnings multiples, given that P/E, forward P/E, EV/EBITDA, and EPS are all unavailable?
- What drove the decline in revenue from $8.0M in FY 2024 to $0.3M in FY 2025, and is there a path back to revenue?
- Debt is reported as N/A in every period while Debt/Equity is 0.5; what is the actual debt composition and maturity profile?
- What is the cash runway given $5.0M in cash against $-3.7M of FY 2025 free cash flow?
- Does the USPTO Notice of Allowance for VT-1908 have any commercialization, licensing, or partnering timeline attached to it?
HIND Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Vyome Holdings Inc. (HIND) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 16h ago
Vyome Holdings, Inc. Estimates – NASDAQ:HIND TradingView report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 19h ago
Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School Yahoo Finance report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 22h ago
Vyome at Chardan healthcare conference: lean biotech bets on rare wounds Investing.com report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market Yahoo Finance report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
AZR Stock Price and Chart — BOATS:AZR TradingView report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago
HIND Q2 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift Shares - Interim Report https://www.dars.gov.et/ report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 1d ago
Vyome Holdings, Inc. (HIND) Stock Price Prediction for 2026, 2030-2040 Traders Union report covering Vyome Holdings Inc. (HIND) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
HIND Bull vs. Bear Conversation Board — What's Your Call at $1.80?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HIND 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $1.54 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is HIND (E • RQD 29/100) a Buy at $1.75?
Welcome to the HIND (Vyome Holdings Inc.) Roar Pit. Current RQD Composite is 29/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $1.44 (-17.7%)
Spot @ $1.75 Pump the brakes on HIND — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on HIND, but look at what you are paying: current EV/EBITDA multiples with 68.4% gross margins. Unless Vyome Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $2.12 (+21.1%)
Spot @ $1.75 HIND cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on HIND, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.75 (52-wk range $1.62 - $6.56), any beat on forward guidance forces shorts and underweight funds to chase.